Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Biotechs: Still Well Placed For More Gains

9h seekingalpha
Big Pharma has to build out pipelines in new areas, and M&A is a compelling alternative. (719-2)

Your Daily Pharma Scoop: AbbVie's Upadacitinib, Johnson & Johnson's Tremfya, Celgene Reports Results For Otezla

2018-02-19 seekingalpha
Today we will discuss AbbVie (ABBV), which continues to have a phenomenal run in 2018 even as sentiment on the broader equity market has turned negative. (144-0)

FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review

2018-02-16 zacks
Agios Pharmaceuticals, Inc. (AGIO - Free Report) announced that the FDA accepted the company’s new drug application (“NDA”) for its isocitrate dehydrogenase 1 (IDH1) mutant inhibitor ivosidenib (AG-120). The company is seeking to get ivosidenib approved for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (“AML”) with an IDH1 mutation. The FDA granted priority review to the candidate and set an action date of Aug 21, 2018. (131-0)

AGIO / Agios Pharmaceuticals, Inc. S-8

2018-02-16 sec.gov
S-8 As filed with the Securities and Exchange Commission on February 14, 2018 Registration No. 333-                       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933     Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter)       Delaware   26-0662915 (State or Other Jurisdiction of Incorporation or Organization)   (I.

BRIEF-Agios says FDA Accepts NDA And Grants Priority Review For Ivosidenib

2018-02-15 reuters
* FDA ACCEPTS NEW DRUG APPLICATION AND GRANTS PRIORITY REVIEW FOR IVOSIDENIB IN RELAPSED OR REFRACTORY AML WITH AN IDH1 MUTATION (9-0)

Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y

2018-02-15 zacks
Agios Pharmaceuticals, Inc. (AGIO - Free Report) posted fourth-quarter 2017 loss of $1.81 per share, wider than both the Zacks Consensus Estimate of a loss of $1.65 and the year-ago loss of $1.34. (100-0)

AGIO / Agios Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A (Passive Investment)

2018-02-14 sec.gov
SC 13G/A     United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)*     AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing This Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d)   * Th

AGIO / Agios Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A (Passive Investment)

2018-02-14 sec.gov
SC 13G/A     United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)*     AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing This Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d)   * Th

Agios Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides

2018-02-14 seekingalpha
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings call. (9-0)

AGIO / Agios Pharmaceuticals, Inc. 10-K (Annual Report)

2018-02-14 sec.gov
Document Table of Contents   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36014 AGIOS PHARMACEUTICALS, INC.

Agios (AGIO) Q4 Loss Wider than Expected; Sales Miss

2018-02-14 zacks
Agios Pharmaceuticals, Inc. (AGIO - Free Report) is a development-stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders. (14-0)

AGIO / Agios Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-02-14 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2018     Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)       Delaware   001-36014   26-0662915 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.

AGIO / Agios Pharmaceuticals, Inc. / Capital International Investors - SC 13G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Agios Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this

AGIO / Agios Pharmaceuticals, Inc. / Capital International Investors - SC 13G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Agios Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this


CUSIP: 00847X104